Wall Street brokerages forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report ($1.52) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.05) and the lowest estimate coming in at ($1.75). Alnylam Pharmaceuticals posted earnings per share of ($1.25) in the same quarter last year, which would suggest a negative year-over-year growth rate of 21.6%. The firm is expected to issue its next earnings report on Friday, May 4th.
On average, analysts expect that Alnylam Pharmaceuticals will report full-year earnings of ($6.81) per share for the current year, with EPS estimates ranging from ($8.01) to ($4.90). For the next financial year, analysts forecast that the firm will post earnings of ($5.58) per share, with EPS estimates ranging from ($6.41) to ($4.55). Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the consensus estimate of ($1.38) by ($0.10). The firm had revenue of $37.90 million for the quarter, compared to analysts’ expectations of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. Alnylam Pharmaceuticals’s revenue was up 116.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.32) EPS.
ALNY has been the subject of a number of research reports. Morgan Stanley boosted their price target on shares of Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 9th. Cowen reissued a “buy” rating and issued a $151.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 9th. Credit Suisse Group boosted their price target on shares of Alnylam Pharmaceuticals from $123.00 to $151.00 and gave the stock an “outperform” rating in a research note on Friday, November 3rd. Leerink Swann boosted their price target on shares of Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a “market perform” rating in a research note on Thursday, January 25th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $152.00 price target (up previously from $125.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $126.76.
In related news, VP Michael Mason sold 36,745 shares of the company’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the sale, the vice president now directly owns 6,352 shares in the company, valued at approximately $835,859.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Laurie Keating sold 30,000 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the sale, the senior vice president now owns 41,500 shares of the company’s stock, valued at $5,639,435. The disclosure for this sale can be found here. Insiders have sold a total of 146,409 shares of company stock valued at $19,279,377 over the last quarter. 4.30% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. Strs Ohio bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $141,000. CENTRAL TRUST Co raised its holdings in Alnylam Pharmaceuticals by 746.3% during the 4th quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 1,000 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $165,000. Fayerweather Charles bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $230,000. Finally, Watch Point Trust Co bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $235,000. Institutional investors own 88.61% of the company’s stock.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $122.88 on Monday. The company has a market cap of $12,271.76, a P/E ratio of -22.71 and a beta of 2.69. Alnylam Pharmaceuticals has a 12 month low of $45.00 and a 12 month high of $147.63. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.23 and a current ratio of 12.23.
TRADEMARK VIOLATION WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/19/1149914.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.